drugset / Trial / NCT02960711

Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome

NCT02960711 ↗

RandomizedFactorialDouble-blindPrevention

Summary

Phase III randomized controlled trial on men and women with Metabolic syndrome (MetS) to test the hypothesis that comprehensive life-style changes and/or metformin treatment prevent age-related chronic non-communicable diseases (ArCD). The aim of the present study is to evaluate the effect of a comprehensive life-style intervention (including moderate physical activity and Mediterranean/macrobiotic diet with moderate calorie and protein restriction), and of treatment with Metformin (a calorie restriction mimetic drug) for the prevention of ArCD.

Timeline

Start
2014-02
Primary completion
2019-07
Completion
2019-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 850 mg Oral

Indications